


**Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)**

Integrated Care Partnerships (ICPs) (Surrey Downs, Guildford & Waverley,  
North West Surrey, East Surrey & associated partner organisations.

<b>Title of paper:</b>	Recommendation to change all guidance from Circadin 2mg MR tablets to generic melatonin 2mg MR tablets		
<b>Meeting date:</b>	June		
<b>Agenda item:</b>	To be completed by APC secretary	<b>Attachment(s):</b>	
<b>Author and contributors:</b>	Lis Stanford & Alison Marshall		
<b>Paper type</b>			
<b>For:</b>	Agreement		
<b>Executive Summary:</b> <i>(provide a short description of the subject matter and draw attention to the issues / facts and the proposal)</i>			
<p>Melatonin 2mg MR tablets are now available generically and are in Category M of the Drug Tariff (£10.38/30 DT May 2022) whereas Circadin 2mg MR tablets are priced at £15.39</p> <p>Branded Circadin is recommended in a number of documents on the PAD and it is requested that these can be changed to generic.</p> <p>Windfall savings from Category M drop in price on existing prescribing will be around £129,000 but there is also potential for switches from brand to generic which will generate more savings. It is also important that any new initiations are of generic.</p> <p>An Excel sheet is embedded below of the statements and documents that will need to be amended.</p>			
 <p>Melatonin PAD review.xlsx</p>			
<p>This request is in line with APC recommendation around generic prescribing which is available on the <a href="#">PAD</a> and states that “The APC support the principle that, where generic medicines are available and there is no clinical rationale for the use of a particular brand, prescribers are requested to prescribe generically” and “Patients already receiving branded medicines should be reviewed and switched to the generic alternative if there is no clinical rationale for the brand.”</p> <p>There is already a PIL available on the <a href="#">PAD</a> that could be used to support the switch.</p> <p>This recommendation links with a request for a formulary extension for melatonin IR tablets which will remove the requirement to crush modified release tablets (off-label use) in some situations.</p>			

**Summary:** *(What is the APC being asked to do and why)*

APC is asked to

- Recommend that melatonin 2mg MR tablets are prescribed generically
- Agree to the change of all documents on the PAD from the brand Circadin to generic. This will allow OptimiseRx messages to be developed to support the change, which is also part of the Surrey Heartlands QIPP plan.
- Recommend switching existing patients being prescribed branded Circadin to generic
- Add preferred products to the policy statement on Parkinsons

**Accompanying papers (please list):**

1)